Zepbound (Tirzepatide) Does Not Cause Oily Stools
Zepbound does not cause oily stools as a recognized side effect. The gastrointestinal adverse events associated with tirzepatide are primarily nausea, vomiting, diarrhea, constipation, decreased appetite, and dyspepsia—but not the oily or fatty stools (steatorrhea) characteristic of medications like orlistat that block fat absorption 1.
Gastrointestinal Side Effects Profile
The most comprehensive safety data shows tirzepatide causes the following GI manifestations 1:
- Nausea: 20.43% (vs 10.47% placebo) - most common side effect
- Diarrhea: 16.24% (vs 8.63% placebo) - regular watery diarrhea, not oily
- Decreased appetite: 9.64% (vs 2.88% placebo)
- Vomiting: 9.05% (vs 4.86% placebo)
- Dyspepsia: 7.13% (vs 3.31% placebo)
- Constipation: 2.54% (vs 0.856% placebo)
These events are typically mild to moderate in severity and are dose-dependent 2, 3, 4. The mechanism is related to GLP-1 receptor activation causing delayed gastric emptying and central appetite suppression—not malabsorption of dietary fat.
Key Distinction from Fat Malabsorption
Oily stools occur with lipase inhibitors (like orlistat) that prevent fat digestion and absorption. Tirzepatide works through completely different mechanisms:
- Dual GIP/GLP-1 receptor agonism
- Enhanced insulin secretion
- Delayed gastric emptying
- Central appetite regulation
There is no fat malabsorption mechanism with tirzepatide, so oily/greasy stools should not occur.
Clinical Implications
If a patient on Zepbound reports oily stools:
- Consider alternative diagnoses (pancreatic insufficiency, celiac disease, bile acid malabsorption, concurrent orlistat use)
- Review all medications and supplements
- Evaluate for underlying GI pathology
- The oily stools are not attributable to tirzepatide
The diarrhea from tirzepatide, when it occurs, is watery—not fatty or oily in character 1.